中国药理学通报2024，Vol.40Issue(8)：1429-1436,8.DOI:10.12360/CPB202210094
PD-1/PD-L1抑制剂联合抗血管内皮生长因子药物免疫治疗晚期肝癌的研究进展
Research progress on combined immunotherapy with PD-1/PD-L1 inhibitors and anti-VEGF agents in advanced hepatocellular carcinoma
摘要
Abstract
Hepatocellular carcinoma(HCC)is one of the most common malignant tumors globally.Programmed death protein-1(PD-1)/programmed death protein ligand-1(PD-L1)inhibitors promote the reactivation of anti-tumor immune response by bloc-king the negative modulatory signaling pathway of T cells'activa-tion and inhibiting the immune escape pathway of tumor cells.PD-1/PD-L1 inhibitors become a novel therapeutic strategy to treat HCC.However,long-term clinical outcomes show that HCC patients treated with anti-PD-1/PD-L1 monotherapy still have high rates of recurrence and metastasis.Combination immuno-therapy is a novel therapeutic strategy to treat advanced HCC pa-tients,among which PD-1/PD-L1 inhibitors in combination with anti-vascular endothelial growth factor(VEGF)agents have showed promising efficacy and better safety.PD-1/PD-L1 inhib-itors plus anti-VEGF agents combined therapy inhibit the growth of hepatoma cells by participating in the cancer immunity cycle pathway.This review focuses on the research progress of PD-1/PD-L1 inhibitors,anti-VEGF agents and their combined therapy in the clinical treatment of HCC.关键词
PD-1/PD-L1抑制剂/抗VEGF药物/免疫联合疗法/肝细胞癌/抗血管生成/癌症免疫循环Key words
PD-1/PD-L1 inhibitors/anti-VEGF agents/combi-nation immunotherapy/hepatocellular carcinoma/anti-angiogen-esis/cancer immunity cycle分类
医药卫生引用本文复制引用
黄燕妮,蓝雪灵,朱敏敏,韦锦斌,李艳,董敏..PD-1/PD-L1抑制剂联合抗血管内皮生长因子药物免疫治疗晚期肝癌的研究进展[J].中国药理学通报,2024,40(8):1429-1436,8.基金项目
国家自然科学基金青年基金资助项目(No 81302859) （No 81302859）
广西自然科学基金面上项目(No 2021GXNSFAA196070,2018GXNSFAA050121) （No 2021GXNSFAA196070,2018GXNSFAA050121）
广西壮族自治区大学生创新创业训练项目(No 202110598158,202110598117) （No 202110598158,202110598117）
